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To assess the views of potential end-users of a microbicide in KwaZulu-Natal regarding the characteristics that
would justify further development, three focus group discussionswere conducted in 2009with 23 local staff members
working on amicrobicide clinical trial, 20 former trial participants and 14CommunityAdvisoryBoardmembers not
enrolled in the trial, in an areawith highHIV incidence and lowconsistent condomuse.All participants agreed on the
need for additionalHIV prevention options that are as effective as possible and can be used by women. Themajority
of respondents stated that even a highly acceptableHIV prevention optionwith protection as low as 30%would still
be an important addition to condoms forwomen; that a partially protectivemicrobicidewould have to be introduced
as part of the existing preventionmessages in order to continue promoting condom use; that there should eventually
be a choice between antiretroviral (ARV) and non-ARV-basedmicrobicides and a choice of how andwhere to access
microbicides. Respondents also felt it would be important to make plans for access to a microbicide that can offer
protection, even if partial, rather than wait to find out if alternative microbicides are equally or more effective.
Potential end-users in a highHIVprevalence area believe that a partially effectivemicrobicidewould be an important
addition to the limited HIV prevention options for women. The significant challenges of introducing a partially
protectiveHIVprevention optionwere recognised, but seen as ones worth facing, as well as an opportunity to lay the
ground work for the introduction of more efficacious HIV prevention methods in the future.
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Introduction
Vaginal microbicides are experimental products being
evaluated to find out if they reduce the risk of HIV
infection in women during sexual intercourse. In
February 2009 the HPTN035 phase IIb clinical trial
reported that 0.5% PRO2000/5 microbicide showed a
30% reduction in vaginally acquired HIV infection
compared with a placebo, but the result was not
statistically significant (Abdool-Karim et al., 2011).
PRO2000/5 is a naphthalene sulphonate polymer
which disrupts the attachment and fusion steps in
HIV infection of target cells. The larger phase III
Microbicides Development Programme (MDP) 301
clinical trial (Nunn et al., 2009) was due to report on
the effectiveness of 0.5% PRO2000/5 at the end of
2009. The World Health Organization (WHO) con-
vened a consultation in London in May 2009 to
prepare for access to 0.5% PRO2000/5 in anticipation
of a significant result. At the meeting there was a
debate regarding the level of effectiveness that
PRO2000/5 would have to demonstrate to garner
support from researchers, policy-makers and advo-
cates for further investment and development. The
threshold for development differed widely, ranging
from 20 to 80%, among representatives from diverse
constituencies. The report noted that it would be
important to engage women at risk of HIV infection,
as the ultimate beneficiaries of microbicides, in future
discussions regarding acceptable minimal levels of
effectiveness (WHO, 2010).
The potential for a reduction in condom use as a
result of the availability of a partially protective
microbicide was also discussed at the meeting,
although there was no consensus as to the weight
that should be placed on such concerns. Mathema-
tical modelling suggests that in areas of high HIV
incidence with low rates of consistent condom use,
even an inconsistently used 40% effective microbicide
would avert a substantial number of HIV infections
(Vickerman et al., 2006). Modelling also suggests that
in areas with 50% or less consistent condom use,
condom use would have to reduce by a third or more
for the net benefit of a 40% effective microbicide to
be negated (Foss, Vickerman, Heise, & Watts, 2003).
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Disappointingly, MDP 301 established that 0.5%
PRO2000/5 did not prevent HIV infection in women
(McCormack et al., 2010). However, in July 2010 the
Centre for the AIDS Programme of Research in South
Africa (CAPRISA) 004 trial demonstrated that an
antiretroviral (ARV) based vaginal microbicide gel
containing tenofovir, when used before and after sex,
reduced the risk of HIV infection in women by 39%
(95% CI: 6, 60) compared with a placebo (Abdool-
Karim et al., 2010). Since this ground-breaking result,
the picture has become less clear. In November 2011
the Microbicide Trials Network VOICE (Vaginal and
Oral Interventions to Control the Epidemic) trial
discontinued daily dosing with tenofovir gel after an
interim analysis revealed that there was no possibility
of demonstrating benefit (MTN, 2011b). The Follow
on Africa Consortium for Tenofovir Studies (FACTS)
001 trial is repeating the CAPRISA 004 trial design in
broader populations in South Africa evaluating peri-
coital use of tenofovir gel and is expected to report
results in 2013 (FACTS, 2012). The only other on-
going microbicide trials are the International Partner-
ship for Microbicides and the Microbicide Trials
Network trials evaluating the ARV dapivirine in a
slow release vaginal ring (MTN, 2012).
The use of ARVs as oral pre-exposure prophylaxis
has been assessed in five trials (Baeten et al., 2012;
Grant et al., 2010; MTN, 2011a; Thigpen et al., 2012;
Van Damme et al., 2012b). A range of effect sizes
from no protection to 73% reduction in HIV
incidence have been observed. Three of these trial
populations were comparable to the CAPRISA 004
trial population (i.e., HIV-negative women in sub-
Saharan Africa whose partners’ HIV status was
unknown). Although 49% reduction in HIV acquisi-
tion was seen in young females in Botswana using
oral Truvada (Thigpen et al., 2012), no protection
was observed with this drug in the FEM-PrEP study
among women in South Africa, Kenya and Tanzania
(Van Damme et al., 2012b). The reasons for the
conflicting results for the same drug in women in
similar epidemic settings are still being evaluated
(Celum & Baeten, 2012), but cannot be explained
by biology alone (Van Damme et al., 2012a).
Vaginal microbicides may still offer the best levels
of protection for womenwho do not know the status of
their partners. Pharmacological studies provide evi-
dence that topical application of tenofovir 1% gel
leads to higher levels of drug in the vagina, compared
with oral administration (Schwartz et al., 2011). In the
VOICE trial, the oral tenofovir arm has been discon-
tinued (MTN, 2011a), while the study continues with
the oral Truvada arm and the final trial report is
expected in 2013 (MTN, 2011c). The question still
remains about the minimum level of protection that a
vaginal microbicide would have to demonstrate in
order to be considered a viable HIV prevention option.
The Africa Centre for Health and Population
Studies (http://www.africacentre.ac.za) was one of
six research centres that participated in the MDP
301 clinical trial. The Centre is located in a predomi-
nantly rural area of the Umkhanyakude District in
KwaZulu-Natal, South Africa (Tanser et al., 2007).
HIV incidence in the area in 20032005 was 3.8 per
100 person years for women aged 1549, peaking
at 8.0 per 100 person years in women aged 2529
(Ba¨rnighausen et al., 2008). Current data on consis-
tent condom use in the general population in the
province is limited, but available evidence suggests
that it is substantially below 50% (Chimbindi,
McGrath, Herbst, San Tint, & Newell, 2010; Maharaj
& Cleland, 2005; Ngubane et al., 2008).
In this study, conducted in July 2009 prior to the
release of the MDP 301 trial results, potential end-
users were asked about the level of effectiveness that
PRO2000/5 would have to demonstrate in order to
garner their support for further development in South
Africa. We conducted focus group discussions
(FGDs) with MDP staff members from the area,
former MDP 301 trial participants, and members of
the Africa Centre Community Advisory Board (CAB)
who were not enrolled in the trial but serve an
advisory function across all Africa Centre studies.
Each of these groups was very familiar with the MDP
301 protocol and that the protocol was designed to
detect a 3540% reduction in HIV incidence. They
had also been regularly updated during presentations
by the MDP team on other developments in the field,
such as the Cellulose Sulphate, SAVVY, Carraguard
and HPTN035 microbicide trial results (Abdool-
Karim et al., 2011; Feldblum et al., 2008; Horwood,
2007; Peterson et al., 2007; Skoler-Karpoff et al.,
2008), the discontinuation of 2% PRO2000/5 (MDP,
2008), the start of the CAPRISA 004 tenofovir
microbicide trial (Abdool-Karim et al., 2010) and
results from the circumcision trials (Bailey et al.,
2007). The way in which trial results are reported had
also been explained to these groups in terms of
understanding different levels of effectiveness.
This study contributes to the on-going debate
regarding the access to partially effective microbicides
andmore broadly the partially effectiveHIVprevention
methods, by reporting the views of potential end-users.
Methods
Three FGDs were conducted, one with 20 female and
3 male MDP staff members, one with 20 former MDP
301 trial participants and one with 8 female and
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6 male CAB members. In total there were 48 women
and 9 men involved in the FGDs. All participants
provided written informed consent. The clinical trial
was approved by the Medicines Control Council
(N2/19/8/2) and the University of KwaZulu-Natal
Biomedical Research Ethics Committee (T111/05).
The discussion was framed on the hypothetical
assumption that 0.5% PRO2000/5 would demon-
strate a partial protection at a statistically significant
level in the MDP 301 trial. Within this context, FGD
participants were asked to discuss the minimum level
of protection they would want PRO2000/5 to demon-
strate in order for it to be considered an HIV
prevention option in South Africa. They were also
asked to discuss whether they would still want
PRO2000/5 to be available if ARV-based microbi-
cides (used pericoitally in the same way as PRO2000/
5) were found to offer twice as much protection as
PRO2000/5 in the future. The groups were asked to
indicate their position on the topics under discussion
by standing on one side of the room or the other
(Winch, Wagman, Malouin, & Mehl, 2000). Some
people in each group were then asked to explain the
reasons behind their choices, and opposing views
were discussed. Notes of the proceedings were taken
by two research assistants independently. Both sets of
notes were transcribed in English. The FGD tran-
scripts were systematically reviewed and manually
coded by the first and second authors.
Results
Table 1 shows the results on the level of effectiveness
that each group would want 0.5% PRO2000/5 to
demonstrate in order to eventually be made available
in their community. All participants agreed on the
need for additional HIV prevention options that
could be used by women. The majority of respon-
dents in all FGDs stated that PRO2000/5 should be
available at any level of effectiveness if the MDP 301
trial result is statistically significant, because it would
give women who could not negotiate condoms a risk
reduction option that they could use, it was highly
acceptable to both women and men and it assisted in
condom negotiation. Former trial participants stated
that the gel had a positive impact on sexual pleasure
and provided lubrication which made condom use
more tolerable to both them and their partners.
Forty-seven of the 57 respondents (82%) argued
that in the light of the extensive HIV epidemic in
the Umkhanyakude District, women who could not
consistently use condoms needed a microbicide that
could offer even 30% protection.
On the other hand, 10 respondents, that is, 3 staff
members (2 females and 1 male), 4 trial participants
and 3 CAB members (1 female and 2 males), did not
think that PRO2000/5 should be available at 30%
effectiveness. These respondents were concerned
about how a 30% effective product would be
explained and rolled out in the government services.
The rest of the respondents acknowledged that it
would be more difficult to explain microbicides in
government services than in clinical trial settings, but
argued that it was possible. The 10 respondents who
did not think that PRO2000/5 should be available at
30% all felt that the attraction of a novel prevention
option could negatively impact on condom use. They
believed that the benefits of rolling out a microbicide
that could halve the risk of infection outweighed the
associated risks of reducing condom use, whereas
they did not believe that the benefits of rolling out a
microbicide that could only reduce the risk by a third
outweighed the risks. In response, other respondents
in each of the FGDs argued strongly that the people
who use condoms consistently and continuously are
the ‘‘converted few’’ who will keep using condoms.
They said that PRO2000/5 will be attractive to those
who do not use condoms or use them inconsistently.
All respondents agreed that any additional preven-
tion option that was not as efficacious as condoms
would have to be introduced in combination with
comprehensive educational programmes as an addi-
tion to the existing HIV prevention messages and, if
done so correctly, could have a positive impact on
condom use. The introduction of a partially protec-
tive microbicide as the fourth-level message for
women (after abstinence, be faithful, use condoms)
was viewed as equivalent to the introduction of
circumcision, which is only partially effective, as
the fourth-level message for men. However, the
Table 1. Proportion of respondents in each FGD who voted for 0.5% PRO2000 to be available at different levels of
effectiveness.
Staff Participants CAB
Effect size (%) Female (n20) Male (n3) Female (n20) Female (n8) Male (n6) Total (n57)
50 20 (100%) 3 (100%) 20 (100%) 8 (100%) 6 (100%) 57 (100%)
40 18 (90%) 2 (67%) 20 (100%) 8 (100%) 6 (100%) 54 (95%)
30 18 (90%) 2 (67%) 16 (80%) 7 (88%) 4 (67%) 47 (82%)
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additional challenge of a microbicide being coitally
dependent was acknowledged.
Twenty-two of the 23 staff members, all of the
participants and 12 of the 14 CAB members would be
in favour of having access to both non-ARV- and
ARV-based microbicides in the future, even if
non-ARV-based products were less effective than
the ARV-based ones. The preference for non-ARV-
based microbicides was largely due to a desire for
HIV prevention options that require minimal medical
management and could therefore be easily available.
The main reasons were (1) they would want the
ability to choose between systemically and non-
systemically absorbed microbicides (largely driven
by their knowledge of side effects with therapeutic
ARVs and their desire to avoid these side effects in
HIV prevention options), (2) that an ARV-based
microbicide may remain under more restricted access
from health care providers than a non-ARV-based
product, (3) that the need for HIV testing before
dispensing ARV-based microbicides could be a bar-
rier to access for some people, (4) that people needed
multiple prevention options to choose from to meet
their various preferences and (5) that they need
additional options as soon as possible. Several
respondents commented that implementing a par-
tially protective microbicide within the next few years
could pave the way for implementing more potent
microbicides (ARV- and non-ARV based) at a later
stage in terms of distribution messages and strategies.
Discussion
Three main issues emerged from these discussions.
First, even a partially protective HIV prevention
option that is highly acceptable would be an im-
portant addition to condoms for women and should
be made available rather than waiting to find out if
alternative microbicides are equally or more effective.
This urgency is reflected by the very high proportions
wanting a partially effective microbicide to be avail-
able across the three categories of potential end-users
in this study, and the higher proportions of females
voting for access at lower effectiveness levels com-
pared to males. Second, any prevention option that is
less efficacious than condoms would have to be
introduced as part of the existing HIV prevention
messages in order to avoid a reduction in condom use
among people willing and able to use condoms.
However, developing appropriate messages around
partial effectiveness was seen as a challenge rather
than a barrier to access. Third, the introduction of
ARV-based microbicides would have to be an addi-
tion to, not a replacement for, a non-ARV-based
microbicide, as eventually there should be a choice of
how and where to access microbicides. These findings
echo arguments recently used by researchers to call
for continued development of non-ARV-based mi-
crobicides (Omar & Bergeron, 2011).
There are two notable limitations to this study.
First, this study did not consider the cost effectiveness
of microbicides (Williams, Abdool Karim, Karim, &
Gouws, 2011), the challenges of evaluating new
microbicide and oral PrEP candidates against par-
tially protective available products, the broader
public health impact of rolling out microbicides, or
the many logistical challenges involved with imple-
mentation. These factors will need to be considered
by researchers, policy-makers and advocates, but did
not emerge in this discussion with potential end-users.
Second, the respondents could all be considered to
have a vested interest in microbicides as they had
been engaged in the research agenda for a number of
years. However, evidence regarding community per-
ceptions of the acceptable minimal levels of protec-
tion has been limited to date despite an abundance of
literature on microbicide acceptability (Hoffman,
Cooper, Ramjee, Higgins, & Mantell, 2008; Mantell
et al., 2005), and this study gives a voice to potential
end-users and contributes to the important discussion
about HIV prevention options.
In conclusion, potential end-users in an area with
highHIV incidence view the introduction of a partially
protective microbicide, in the context of a well-
positioned and well-funded introductory programme,
as an opportunity to expand the existing HIV preven-
tion package. Potential end-users are aware of the
significant challenges to introducing a partially pro-
tective HIV prevention option, but believe that they
are challenges worth facing and provide an opportu-
nity to lay the ground work for the introduction of
more efficacious HIV prevention methods in the
future. These views remain highly relevant to the
recent progress in the field of microbicide research
and HIV prevention research more generally.
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